Home / Themes / MedTech Short '25: Heavy China Exposure
MedTech Short '25: Heavy China Exposure (view performance)
Last updated
Theme thesis · 3/5 sections · Tickers 7 with notes · 4 pending
Bull / Bear Details has the investment thesis and bull/bear points. Overview is monitoring guidance (hiring, forums, second-order trends, search keywords, Google Trends, datasets).
Bull / Bear DetailsEven though the BIOSECURE Act did not pass in April, the Trump 2.0 administration has signaled ongoing hostility toward China-linked biopharma operations. De fa
Thesis
Even though the BIOSECURE Act did not pass in April, the Trump 2.0 administration has signaled ongoing hostility toward China-linked biopharma operations. De facto pressure is being exerted through executive actions, federal agency contract constraints, and rhetorical/political overhangs. That's already driving anticipatory behavior—such as supply chain restructuring, domestic capex shifts, and RFP rerouting—hurting multinationals with large China exposure.
Bull case
Policy Pressure Despite Legislative Delay: Even without passage, agencies are quietly shifting procurement preferences away from companies with Chinese dependencies. Sentiment remains highly negative for bio multinationals.
Early Capex Shifts & Contract Losses: Anecdotal reports from smaller domestic players (TKNO, NOTV) indicate new client wins and RFP redirection from China-exposed competitors like DHR, IQV even in the absence of a formal mandate
China Still a Fundamental Drag: China remains a weak spot in life science earnings reports (e.g., WAT, DHR), as sentiment, pricing pressure, and trade disruptions persist amid broader U.S.-China decoupling dynamics
Bear case
BIOSECURE Act Failure Buys Time: With the act failing to pass, companies like DHR, IQV, and TECH get breathing room to adapt operations, lobby for exemptions, and avoid abrupt revenue loss or contract restrictions.
Stimulus & Stabilization in China and EU: Signs of stabilization in Chinese demand and fresh EU health system stimulus (including for diagnostics and biologics) could support revenue rebounds for multinationals with deep overseas exposure.
U.S. Cost Inflation & Supply Chain Complexity: Over-rotation into U.S.-only manufacturing could expose domestic players to capacity constraints and margin pressure, potentially making global, diversified firms like AMGN or NVO more competitive on cost and innovation.
Key Metrics
| Metric | Cadence | What It Signals | Update Source |
|---|---|---|---|
| CRO/CDMO RFP Shifts from China to U.S. Providers | Quarterly | Measures dealflow and outsourcing shifts; a pivot away from IQV/DHR favors the short thesis. | Google_Sheets |
| Biopharma & Medtech Export Volume to U.S. (China & EU) | Monthly | Tracks trade rerouting and pressure from onshoring; falling volumes confirm thesis. | Google_Sheets |
| Company-Specific China Revenue and Commentary | Quarterly | Reveals demand softness, FX headwinds, and structural erosion in China exposure. | Google_Sheets |
Upcoming Catalysts
| Catalyst ID | Estimated Timing | Estimated Date Start | Estimated Date End | Catalyst | Why It Matters | Ticker Or Theme Specific | Transcript Date | Source Type | Catalyst Source |
|---|---|---|---|---|---|---|---|---|---|
| AMGN_17b91ee0 | study completion expected in 2026. | 2026-07-01 | 2026-12-31 | Completion of both Phase III studies for desodoliveb, a CD40 ligand targeting biotherapeutic, in Sjogren's disease. | Study completion is a critical step before data readout and potential regulatory filings, which could position desodoliveb as a significant treatment option in a challenging autoimmune condition. | Ticker | 2026-02-03 | earnings_transcript | AMGN (ticker) |
| AMGN_fe4d51bf | We will update you on those discussions as necessary. | 2026-04-24 | 2026-12-31 | Resolution of ongoing discussions with the FDA regarding TABNIO's (avacopan) following a voluntary withdrawal request related to primary endpoint result readjudication. | The outcome will determine the future commercial viability of TABNIO's, impacting Amgen's rare disease portfolio and potentially leading to a re-evaluation of the product's sales trajectory. | Ticker | 2026-02-03 | earnings_transcript | AMGN (ticker) |
| DHR_2e0838de | later this year | 2026-07-21 | 2026-12-31 | Completion of the pending acquisition of Masimo, subject to customary closing conditions and regulatory approvals. | This strategic acquisition is expected to be accretive to adjusted diluted net EPS in the first full year post-acquisition and deliver high single-digit return on invested capital by the fifth year, enhancing Danaher's acute care diagnostics strategy and offering significant synergies. | Ticker | 2026-04-21 | earnings_transcript | DHR (ticker) |
| DHR_ba441a9a | for the year | 2026-07-01 | 2026-12-31 | Further improvement in Life Sciences end markets, including accelerated growth in China and faster conversion of biotech funding into orders. | This would allow Danaher to achieve the higher end of its 2026 core revenue and adjusted EPS guidance, signaling stronger underlying demand and a more robust recovery in key market segments. | Ticker | 2026-04-21 | earnings_transcript | DHR (ticker) |
| NVO_af1c28d8 | Q3 2026 | 2026-07-01 | 2026-09-30 | First readout of Ziltivekimab from the ZEUS Phase III trial for ASCVD. | This is a high-potential, first-in-class anti-IL-6 treatment for ASCVD, with positive results potentially opening a large new market and validating a new mechanism of action. | Ticker | 2026-05-06 | earnings_transcript | NVO (ticker) |
| ABBV_f4ed1dbb | later this fall | 2026-09-01 | 2026-11-30 | US regulatory approval decision for SKYRIZI subcutaneous induction dosing option in Crohn's disease. | This approval would provide a convenient subcutaneous induction option for Crohn's patients, supported by strong efficacy data, which is expected to accelerate SKYRIZI's capture rate in the IBD market. | Ticker | 2026-07-31 | earnings_transcript | ABBV (ticker) |
| ABBV_b765bcfd | third quarter | 2026-07-01 | 2026-09-30 | FDA approval decision for tevapadone, a novel selective D1/D5 dopamine agonist, for Parkinson's disease. | This approval would enable the launch of a new, highly effective treatment for motor symptoms in Parkinson's, contributing significantly to AbbVie's neuroscience portfolio and its projected $5 billion peak sales for the Parkinson's franchise. | Ticker | 2026-07-31 | earnings_transcript | ABBV (ticker) |
| ABBV_ced91140 | by Q3 or so | 2026-07-01 | 2026-09-30 | Data from two additional cohorts of a Phase 2 study evaluating bradicilacin in major depressive disorder (MDD). | This data will inform the development strategy and Phase 3 plans, with bradicilacin having the potential to be a groundbreaking new treatment in depression due to its strong efficacy and short-acting profile. | Ticker | 2026-02-04 | earnings_transcript | ABBV (ticker) |
| ABBV_800b4101 | an approval decision is anticipated in the third quarter for tevapadon in Parkinson's disease. | 2026-07-01 | 2026-09-30 | US commercial approval decision for tevapadon in Parkinson's disease. | Approval would add a new, potentially multibillion-dollar asset to AbbVie's neuroscience portfolio, offering a new treatment option for Parkinson's disease. | Ticker | 2026-02-04 | earnings_transcript | ABBV (ticker) |
| ABBV_47f622ef | data from both trials expected in the second half of this year. | 2026-07-01 | 2026-12-31 | Data readout from Phase 3 studies evaluating QLIPTA and UBRELVY for menstrual migraine prevention. | Positive data could lead to label expansions for these leading migraine products, addressing a distinct and difficult-to-treat subtype of migraine and further driving sales. | Ticker | 2026-02-04 | earnings_transcript | ABBV (ticker) |
| DHR_f825acc1 | by the end of the year | 2026-10-01 | 2026-12-31 | Abatement of policy headwinds in China diagnostics, normalization of respiratory revenue, and improved year-over-year comparisons in Life Sciences. | The resolution of these headwinds is projected to drive an acceleration in Danaher's core revenue growth, enabling the company to achieve mid-single-digit core growth by the end of Q4 2026. | Ticker | 2026-04-21 | earnings_transcript | DHR (ticker) |
| DHR_0a68fb32 | Q4 | 2026-10-01 | 2026-12-31 | A stronger-than-typical seasonal respiratory infection rate in the fourth quarter of 2026. | A robust respiratory season would contribute to Danaher's goal of returning to an endemic $1.8 billion respiratory revenue rate and help achieve the higher end of its full-year 2026 guidance. | Ticker | 2026-04-21 | earnings_transcript | DHR (ticker) |
| NVO_71e5b33d | at the end of 2026 | 2026-10-01 | 2026-12-31 | FDA regulatory decision for CagriSema in the U.S. for obesity. | Approval would introduce a new, potentially highly effective obesity treatment, strengthening Novo Nordisk's pipeline and competitive position. | Ticker | 2026-05-06 | earnings_transcript | NVO (ticker) |
| ABBV_c5da1469 | later this year | 2026-10-01 | 2026-12-31 | US regulatory approval decision for RINVOQ for the treatment of vitiligo. | This approval would mark RINVOQ as the first systemic treatment for vitiligo, significantly expanding its market potential and contributing to the anticipated combined peak sales of $2 billion for vitiligo and alopecia areata indications. | Ticker | 2026-07-31 | earnings_transcript | ABBV (ticker) |
| IQV_2593c7c7 | December 1-2, 2026 | 2026-12-01 | 2026-12-02 | COG: CRO Summit in North Carolina, focusing on AI integration and clinical trial innovation. | This summit will highlight cutting-edge topics such as AI integration and clinical trial innovation. Key announcements or presentations could reveal new opportunities and competitive advantages for CROs like IQVIA, leveraging advanced technologies and operational efficiencies. | Theme | 2026-05-05 | earnings_transcript | IQV (ticker) |
| IQV_8ae5960d | December 2, 2026 | 2026-12-02 | 2026-12-02 | IQVIA Investor Day. | This event is expected to provide updated strategic insights, long-term financial targets, and new product/technology roadmaps, which can significantly impact investor sentiment and valuation. | Ticker | 2026-07-28 | earnings_transcript | IQV (ticker) |